ImpediMed (ASX:IPD) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IPD 주식 개요

의료 기술 회사인 ImpediMed Limited는 호주, 북미 및 전 세계에서 생체 임피던스 분광법(BIS) 장치 및 소프트웨어 서비스를 개발, 제조 및 판매하는 회사입니다.

IPD 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 67.7% 에서 거래

수익은 연간 39.8% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 4.1% 증가했습니다.

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

ImpediMed Limited 경쟁사

Cyclopharm

ASX:CYC

AU$164.0m

Optiscan Imaging

ASX:OIL

AU$150.4m

Austco Healthcare

ASX:AHC

AU$66.7m

Compumedics

ASX:CMP

AU$56.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 ImpediMed
과거 주가
현재 주가	AU$0.071
52주 최고치	AU$0.24
52주 최저치	AU$0.063
베타	2.8
11개월 변경	-14.46%
3개월 변경 사항	-19.32%
1년 변경 사항	-55.63%
33년 변화	-35.45%
5년 변화	-38.26%
IPO 이후 변화	-91.65%

최근 뉴스 및 업데이트

Recent updates

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Sep 28

We're Not Worried About ImpediMed's (ASX:IPD) Cash Burn

Jun 10

A Look At The Fair Value Of ImpediMed Limited (ASX:IPD)

Feb 01

We Think ImpediMed (ASX:IPD) Can Afford To Drive Business Growth

Aug 25

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Apr 06

Analysts Expect Breakeven For ImpediMed Limited (ASX:IPD) Before Long

Feb 12

ImpediMed's (ASX:IPD) Stock Price Has Reduced 88% In The Past Five Years

Jan 08

How Does ImpediMed's (ASX:IPD) CEO Salary Compare to Peers?

Nov 25

주주 수익률

	IPD	AU Medical Equipment	AU 마켓
7D	2.9%	-2.2%	0.1%
1Y	-55.6%	19.6%	8.5%

수익률 대 산업: IPD 지난 1년 동안 21.4 %를 반환한 Australian Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: IPD 지난 1년 동안 6.7 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is IPD's price volatile compared to industry and market?
IPD volatility
IPD Average Weekly Movement	7.8%
Medical Equipment Industry Average Movement	9.5%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	16.2%
10% least volatile stocks in AU Market	3.2%

안정적인 주가: IPD 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: IPD 의 주간 변동성( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1999	76	Parmjot Bains	www.impedimed.com

의료 기술 회사인 ImpediMed Limited는 호주, 북미 및 전 세계에서 생체 임피던스 분광법(BIS) 장치와 소프트웨어 서비스를 개발, 제조 및 판매합니다. 이 회사는 림프부종을 평가하고 체액 상태 및 조직 구성의 스냅샷을 제공하는 비침습적 BIS 기기인 SOZO, 건강한 개인의 체성분 분석을 위한 단일 채널 4극성 BIS 기기인 SFB7, 동물용 체액 상태 및 조직 구성을 측정하는 단일 채널 4극성(BIS) 기기인 ImpediVET을 제공합니다. 이 회사는 병원과 클리닉에 기기를 판매합니다.

ImpediMed Limited 기본 사항 요약

ImpediMed 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IPD 기본 통계
시가총액	AU$143.64m
수익(TTM)	-AU$19.50m
수익(TTM)	AU$10.47m

13.7x

P/S 비율

-7.4x

P/E 비율

IPD 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IPD 손익 계산서(TTM)
수익	AU$10.47m
수익 비용	AU$1.37m
총 이익	AU$9.11m
기타 비용	AU$28.60m
수익	-AU$19.50m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.0096
총 마진	86.95%
순이익 마진	-186.16%
부채/자본 비율	0%

IPD 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IPD 주식 개요

보상

위험 분석

ImpediMed Limited 경쟁사

ASX:CYC

AU$164.0m

ASX:OIL

AU$150.4m

ASX:AHC

AU$66.7m

ASX:CMP

AU$56.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Recent updates

ImpediMed Limited Appoints Fiona Bones as A Non-Executive Director

New minor risk - Market cap size

Independent Non-Executive Director recently bought AU$50k worth of stock

ImpediMed Limited to Report Q3, 2024 Results on Apr 30, 2024

Price target decreased by 9.6% to AU$0.18

ImpediMed to Present Chronic Breast Cancer-Related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Independent Non-Executive Director recently bought AU$100k worth of stock

ImpediMed (ASX:IPD) Is In A Good Position To Deliver On Growth Plans

Consensus revenue estimates decrease by 13%

Independent Non-Executive Director recently bought AU$90k worth of stock

Price target decreased by 12% to AU$0.19

No longer forecast to breakeven

High number of new and inexperienced directors

New minor risk - Share price stability

ImpediMed Limited to Report First Half, 2024 Results on Feb 27, 2024

Independent Non-Executive Director recently bought AU$135k worth of stock

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

Consensus revenue estimates decrease by 20%

ImpediMed Limited Announces CFO Changes

Price target decreased by 16% to AU$0.23

Price target increased by 21% to AU$0.27

ImpediMed Limited to Report Q1, 2024 Results on Oct 31, 2023

ImpediMed Limited, Annual General Meeting, Nov 30, 2023

High number of new directors

ImpediMed Limited Announce the Appointment of Steven Chen as Chief Medical Officer

Consensus revenue estimates decrease by 23%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

ImpediMed Limited, Annual General Meeting, Sep 28, 2023

Price target increased by 27% to AU$0.21

ImpediMed Limited to Report Q4, 2023 Results on Jul 24, 2023

Is ImpediMed (ASX:IPD) In A Good Position To Deliver On Growth Plans?

ImpediMed Limited Appoints Daniel Sharp as Director

Executive Director recently bought AU$144k worth of stock

Independent Non-Executive Chairman recently bought AU$82k worth of stock

No longer forecast to breakeven

MD, CEO & Director recently bought AU$52k worth of stock

MD, CEO & Director recently bought AU$54k worth of stock

Price target increased by 25% to AU$0.18

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

MD, CEO & Director recently bought AU$64k worth of stock

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.006 loss in 1H 2022)

Price target decreased by 7.7% to AU$0.17

ImpediMed Limited to Report Q2, 2023 Results on Jan 30, 2023

ImpediMed Limited Presents New Data at 2022 San Antonio Breast Cancer Symposium Shows Early Detection Using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

Impedimed Limited Announces CEO Changes

ImpediMed Limited Announces Management Changes

Less than half of directors are independent

Executive Director & Interim CEO recently bought AU$164k worth of stock

Less than half of directors are independent

ImpediMed Limited Announces Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer Related Lymphedema

ImpediMed Limited to Report Q1, 2023 Results on Oct 19, 2022

ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer

ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients

Here's Why We're Not Too Worried About ImpediMed's (ASX:IPD) Cash Burn Situation

Consensus forecasts updated

Price target decreased to AU$0.18

ImpediMed Limited Announces Board Changes

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ImpediMed Limited Announces PREVENT Trial Finishes - Final Patient Completes Follow-Up